Miragen Therapeutics (NASDAQ: MGEN) is one of 21 public companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare Miragen Therapeutics to similar companies based on the strength of its analyst recommendations, earnings, profitability, institutional ownership, risk, valuation and dividends.
This table compares Miragen Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Miragen Therapeutics Competitors||-118.65%||-181.74%||-42.76%|
This is a summary of recent ratings and price targets for Miragen Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Miragen Therapeutics Competitors||108||455||531||17||2.41|
Miragen Therapeutics currently has a consensus price target of $17.19, suggesting a potential upside of 166.47%. As a group, “Medical laboratories” companies have a potential upside of 13.14%. Given Miragen Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Miragen Therapeutics is more favorable than its rivals.
Earnings & Valuation
This table compares Miragen Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Miragen Therapeutics||$4.00 million||-$26.51 million||-4.67|
|Miragen Therapeutics Competitors||$1.13 billion||$76.65 million||217.74|
Miragen Therapeutics’ rivals have higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
19.0% of Miragen Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Miragen Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Miragen Therapeutics’ rivals have a beta of 1.23, indicating that their average stock price is 23% more volatile than the S&P 500.
Miragen Therapeutics rivals beat Miragen Therapeutics on 7 of the 13 factors compared.
About Miragen Therapeutics
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.